StockData

Inhibrx Biosciences vs Outlook Therapeutics

INBX and OTLK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INBX and OTLK compare

Inhibrx Biosciences is the larger company, worth 12 times as much as Outlook Therapeutics ($1.1B against $87.8M).

Outlook Therapeutics scores higher on the StockData Score (4 against 1 for Inhibrx Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINBXOTLK
Size and price
Market cap$1.1B$87.8M
Share price$74.18$0.361
Change, 1 year−6.3%−77.0%
Change, 5 years93.5%−98.7%
Beta (5Y)2.163.72
Employees11017
StockData Score
Total score14 (better)
Valuation score00
Growth score00
Performance score00
Health score14 (better)
Dividend score00
Valuation
FCF yield−12.2%–
Growth
Revenue growth, 5Y average−36.8%–
Financial health
Interest coverage−5.9×–
Current ratio7.58 (better)0.81
Altman Z-score−1.02 (better)−40.77
Piotroski F-score11
Dividends and buybacks
Buyback yield–−62.3%
Shareholder yield0.00% (better)−62.3%
Ownership
Held by institutions97.4%8.4%
Held by insiders35.4%28.5%
Insider net buying, 12 months$6.1M$7.9M (better)
Superinvestors holding1–
Short interest, % of float35.7%20.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.